Compare Mongodb Inc (MDB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs ResMed Inc. — how do they compare? Mongodb Inc trades at $370.72 (market cap $29.24B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Mongodb Inc and ResMed Inc. are close in size by market cap, and ResMed Inc. pays a 1.17% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and ResMed Inc. for 51 Days on average.
| MDB | RMD | |
|---|---|---|
Market Cap | $29.24B | $31.78B |
Volume | 1,304,995 | 1,128,382 |
Sector | Technology | Health |
52-Week High | $472.29 | $277.88 |
52-Week Low | $225.95 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | $26.86B | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
